相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
Simona Soverini et al.
BLOOD (2020)
A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients
M. Isabel Prieto-Conde et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia
Georg-Nikolaus Franke et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities
Crescenzio Francesco Minervini et al.
FRONTIERS IN GENETICS (2020)
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
Simona Bernardi et al.
CANCER MEDICINE (2019)
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini et al.
CLINICAL CANCER RESEARCH (2019)
Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia
Manuela Krumbholz et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Leukemia-derived exosomes: Bringing oncogenic signals to blood cells
Hossein Sharifi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript
Kirsty Sharplin et al.
LEUKEMIA RESEARCH (2019)
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
Barbara Izzo et al.
FRONTIERS IN ONCOLOGY (2019)
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Ilaria Del Giudice et al.
FRONTIERS IN ONCOLOGY (2019)
Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia
Simona Bernardi et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2019)
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors
Jorge Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Treatment-Free Remission in CML: the US Perspective
Guru Subramanian Guru Murthy et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia
Cosimo Cumbo et al.
GENES (2019)
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
Ehab Atallah et al.
BMC CANCER (2018)
Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre
Ya-Zhen Qin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression
Wen-Jun Wang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
HAEMATOLOGICA (2018)
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
Ilaria S. Pagani et al.
HAEMATOLOGICA (2018)
Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia
Nicoletta Coccaro et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time
Yong-Qing Tong et al.
LEUKEMIA RESEARCH (2018)
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia
Massimo Breccia et al.
CURRENT ONCOLOGY REPORTS (2018)
Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients
Cosimo Cumbo et al.
Oncotarget (2018)
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
HAEMATOLOGICA (2018)
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
Ilaria S. Pagani et al.
HAEMATOLOGICA (2018)
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia et al.
FRONTIERS IN ONCOLOGY (2018)
A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs
Dorota Link-Lenczowska et al.
ANNALS OF HEMATOLOGY (2018)
Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology
Jerald P. Radich et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia
Paola Orsini et al.
SCIENTIFIC REPORTS (2018)
Is DNA a better assay for residual disease in chronic myeloid leukemia?
Jerald Radich
HAEMATOLOGICA (2018)
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia
Sara Galimberti et al.
FRONTIERS IN ONCOLOGY (2018)
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy
Delphine Rea et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology
Crescenzio F. Minervini et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2017)
A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia
Ilaria S. Pagani et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia
Claudia Brunetti et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
R. Hehlmann et al.
LEUKEMIA (2017)
A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD)
M. -H. Duan et al.
LEUKEMIA RESEARCH (2017)
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
Alice Giustacchini et al.
NATURE MEDICINE (2017)
Remembrance of things past-discontinuation of second-generation TKI therapy for CML
Timothy P. Hughes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
Mohamed El Missiry et al.
PLOS ONE (2017)
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
Valentin Garcia-Gutierrez et al.
PLOS ONE (2017)
Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
Liza Lof et al.
SCIENTIFIC REPORTS (2017)
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response
Junichiro Yuda et al.
CANCER SCIENCE (2017)
BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro
Fen-fen Fu et al.
ACTA PHARMACOLOGICA SINICA (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients
Joost H. van Ginkel et al.
BMC CANCER (2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Rebecca Warfvinge et al.
BLOOD (2017)
Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots
Olga Sala Torra et al.
BLOOD (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Attomolar electrochemical detection of the SCRJABL fusion gene based on an amplifying self-signal metal nanoparticle-conducting polymer hybrid composite
Karen Y. P. S. Avelino et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2016)
TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing
Crescenzio Francesco Minervini et al.
DIAGNOSTIC PATHOLOGY (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients
Mary Alikian et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
Jinheng Wang et al.
JOURNAL OF PATHOLOGY (2016)
NCCN Guidelines® Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
Arnel Pallera et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia
Gareth Gerrard et al.
LEUKEMIA RESEARCH (2016)
Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis
Anna Wojtuszkiewicz et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Best Practices in Chronic Myeloid Leukemia Monitoring and Management
Simona Soverini et al.
ONCOLOGIST (2016)
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
Simona Soverini et al.
ONCOTARGET (2016)
Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects
Martin Culen et al.
ONCOTARGET (2016)
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
Kazuma Ohyashiki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group
Noriyoshi Iriyama et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Silvia Mori et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A review of the European LeukemiaNet recommendations for the management of CML
Michele Baccarani et al.
ANNALS OF HEMATOLOGY (2015)
Natural course and biology of CML
Bradley Chereda et al.
ANNALS OF HEMATOLOGY (2015)
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling
Yuh-Ying Yeh et al.
BLOOD (2015)
A DNA Real-Time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid Leukemia
Paul A. Bartley et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells
L. Mourgues et al.
LEUKEMIA (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing
Jana Linhartova et al.
Molecular Cancer (2015)
A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system
Anoop Enjeti et al.
PATHOLOGY (2015)
BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR
Antonella Zagaria et al.
VIRCHOWS ARCHIV (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
Henrik Hjorth-Hansen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
H. White et al.
LEUKEMIA (2015)
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Harald Herrmann et al.
BLOOD (2014)
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford et al.
BLOOD (2014)
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M. Ross et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia
Peter Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Minimal residual disease testing in hematologic malignancies and solid cancer
Amin Ben Lassoued et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR
Lawrence J. Jennings et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
Michael E. O'Dwyer et al.
LEUKEMIA RESEARCH (2014)
Transferred BCR/ABL DNA from K562 Extracellular Vesicles Causes Chronic Myeloid Leukemia in Immunodeficient Mice
Jin Cai et al.
PLOS ONE (2014)
Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
Junko H. Ohyashiki et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Extracellu ar vesicles as shuttles of tumor biomarkers and anti-tumor drugs
Davide Zocco et al.
FRONTIERS IN ONCOLOGY (2014)
One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a hypoxic environment
Elisabetta Rovida et al.
HYPOXIA (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale
Helen E. White et al.
CLINICAL CHEMISTRY (2013)
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
Antonella Russo Rossi et al.
HAEMATOLOGICA (2013)
Absolute quantification by droplet digital PCR versus analog real-time PCR
Christopher M. Hindson et al.
NATURE METHODS (2013)
Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns
C. E. Lopez-Jorge et al.
ANNALS OF HEMATOLOGY (2012)
Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia
Manuela Krumbholz et al.
GENES CHROMOSOMES & CANCER (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array
Wu Yujie et al.
LEUKEMIA & LYMPHOMA (2012)
Digital PCR hits its stride
Monya Baker
NATURE METHODS (2012)
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation
Alexandra S. Whale et al.
NUCLEIC ACIDS RESEARCH (2012)
Concomitant occurrence of BCR-ABL and JAK2V617F mutation
Lisa Pieri et al.
BLOOD (2011)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
Sensitive DNA impedance biosensor for detection of cancer, chronic lymphocytic leukemia, based on gold nanoparticles/gold modified electrode
Ali A. Ensafi et al.
ELECTROCHIMICA ACTA (2011)
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2011)
Decreased TET2 gene expression during chronic myeloid leukemia progression
F. Albano et al.
LEUKEMIA RESEARCH (2011)
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Rajesh R. Nair et al.
BIOCHEMICAL PHARMACOLOGY (2010)
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells
Aleksandra Rizo et al.
BLOOD (2010)
Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia
Paul A. Bartley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA
P. A. Bartley et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation
J. Score et al.
LEUKEMIA (2010)
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
D. M. Ross et al.
LEUKEMIA (2010)
Standardisation of molecular monitoring for chronic myeloid leukaemia
Nicholas C. P. Cross
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia
Sara Raponi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared with Conventional mRNA Analysis
Elia Mattarucchi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2009)
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients
F. Weerkamp et al.
LEUKEMIA (2009)
Electrochemical Biosensor for Detection of BCR/ABL Fusion Gene Using Locked Nucleic Acids on 4-Aminobenzenesulfonic Acid-Modified Glassy Carbon Electrode
Jinghua Chen et al.
ANALYTICAL CHEMISTRY (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia
Elia Mattarucchi et al.
GENES CHROMOSOMES & CANCER (2008)
A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts
Thomas Burmeister et al.
LEUKEMIA RESEARCH (2008)
Proteomic profiling of exosomes: Current perspectives
Richard J. Simpson et al.
PROTEOMICS (2008)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
S. Branford et al.
LEUKEMIA (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
